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OBJECTIVEdTo evaluate the changes in circulating endotoxin after a high–saturated fat meal
to determine whether these effects depend on metabolic disease state.
RESEARCH DESIGN AND METHODSdSubjects (n = 54) were given a high-fat meal
(75 g fat, 5 g carbohydrate, 6 g protein) after an overnight fast (nonobese control [NOC]: age
39.96 11.8 years [mean6 SD], BMI 24.96 3.2 kg/m2, n = 9; obese: age 43.86 9.5 years, BMI
33.36 2.5 kg/m2, n = 15; impaired glucose tolerance [IGT]: age 41.76 11.3 years, BMI 32.06
4.5 kg/m2, n = 12; type 2 diabetes: age 45.46 910.1Q:1 years, BMI 30.36 4.5 kg/m2, n = 18]. Blood
was collected before (0 h) and after the meal (1–4 h) for analysis.
RESULTSdBaseline endotoxin was signiﬁcantly higher in the type 2 diabetic and IGT subjects
than in NOC subjects, with baseline circulating endotoxin levels 65.3% higher in type 2 diabetic
subjects than in NOC subjects (P, 0.05). Ingestion of a high-fat meal led to a signiﬁcant rise in
endotoxin levels in type 2 diabetic, IGT, and obese subjects over the 4-h time period (P, 0.05).
These ﬁndings also showed that, at 4 h after ameal, type 2 diabetic subjects had higher circulating
endotoxin levels (122.6%↑) than NOC subjects (P , 0.05).
CONCLUSIONSdThese studies have highlighted that exposure to a high-fat meal elevates
circulating endotoxin irrespective of metabolic state, as early as 1 h after a meal. However, this
increase is substantial in IGT and type 2 diabetic subjects, suggesting that metabolic endotox-
inemia is exacerbated after high fat intake. In conclusion, our data suggest that, in a compro-
mised metabolic state such as type 2 diabetes, a continual snacking routine will cumulatively
promote their condition more rapidly than in other individuals because of the greater exposure
to endotoxin.
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S tudies examining the interrelation-ships between adipose tissue, inﬂam-mation, and insulin resistance appear
key to understanding type 2 diabetes risk
(1,2). It is known that low-grade chronic
systemic inﬂammation contributes to this
risk, which appears altered by several fac-
tors such as increasing age, sex, ethnicity,
genetics, and dietary inﬂuences. However,
systemic inﬂammation appears to persist
in type 2 diabetic subjects, despite medica-
tion, while the mechanisms and mediators
of this continual inﬂammation appear less
clear. Evidently, adipose tissue accumula-
tion has a signiﬁcant impact on disease risk
and inﬂammation in type 2 diabetes but
maymerely act in response to systemic pri-
mary insults (3–9).
One potential cellular mechanism for
increased inﬂammation may arise through
activation of the innate immune system
in human adipose tissue (10–13). Previ-
ous studies have shown that increased
activation of the innate immune pathway
may arise through excess circulating
gut-derived bacteria, known as lipopoly-
saccharide(LPS) or endotoxin, which
represents the outer cell wall membrane
of gram-negative bacteria (10,11,14–17).
Our previous work has shown that endo-
toxin has an immediate impact on the in-
nate immune pathway in human adipose
tissue, acting via key receptors known as
the Toll-like receptors, which recognize an-
tigens, such as the LPS component, to ini-
tiate an acute-phase response to infection
(8,10). Stimulation of the Toll-like recep-
tors leads to intracellular activation of nu-
clear factor kB, a key transcription factor
in the inﬂammatory cascade that regulates
the transcription of numerous proinﬂam-
matory adipokines (9,10). Therefore, in vi-
tro endotoxin may act as a mediator of
inﬂammation through activation of nuclear
factor kB, leading to a rapid response
within adipose tissue that may be exacer-
bated by increased adipose tissue mass
(18–22).
However, clinical studies have also
implicated gut-derived endotoxin as a
“primary insult” to activate the inﬂamma-
tory state, contributing to metabolic dis-
ease, with current cross-sectional data
showing elevated systemic endotoxin lev-
els in conditions of obesity, type 2 diabe-
tes, coronary artery disease, and fatty liver
disease (8,10,11,14–17). Within these
studies, circulating endotoxin is observed
to be positively associated with waist,
waist-to-hip ratio, insulin levels, inﬂam-
matory cytokines, and lipids, including
total cholesterol, triglycerides (TGs), and
LDL cholesterol, and negatively associated
with HDL cholesterol (8,10,11,14–17).
The combined importance of dietary lip-
ids and LPS in determining inﬂammatory
risk may arise, since endotoxin has a
strong afﬁnity for chylomicrons (lipopro-
teins that transport dietary long-chain sat-
urated fatty acids [SFAs Q:2] through the gut
wall) as endotoxin crosses the gastrointes-
tinalmucosa (23–25). As such, atherogenic
and inﬂammatory risk may arise through a
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combination of dietary lipoprotein pat-
terns and an increase in circulating endo-
toxin, exacerbated by feeding patterns
(26,27). Therefore, altering the lipid pro-
ﬁle through dietary intervention may
reduce endotoxin and the arising inﬂam-
matory response. Recent human studies
have explored dietary effects of a high-SFA,
high-carbohydrate meal on circulating
endotoxin levels in healthy individuals.
The ﬁndings showed a substantial increase
in circulating endotoxin, in subjects
given a high-fat meal, in conjunction
with markers of inﬂammation (as noted
from mononuclear blood cells) (13,28).
Murine studies have also identiﬁed an
association between endotoxin and insu-
lin resistance, through infusion of endo-
toxin, with the same effect also noted by a
high-fat diet (12), with insulin resistance
and weight gain both affecting gut perme-
ability (11,17,28). In studies to date us-
ing either infused endotoxin as a bolus or
derived from the gut because of dietary
changes, both methods suggest endo-
toxin has the capacity to affect the inﬂam-
matory pathways (28,29). However, it
remains to be established whether diets
in different metabolic states affect absorp-
tion of endotoxin. Also, do such post-
prandial circulating endotoxin levels
correlate with systemic lipid changes
postprandially, being compounded in
more insulin-resistant states? Therefore,
these studies sought to establish whether
a high-fat meal increased circulating en-
dotoxin and whether this is altered in dif-
ferent metabolic disease states.
RESEARCH DESIGN AND
METHODSdThe study consisted of
healthy control subjects (n = 9), obese
subjects (n = 12), and patients with im-
paired glucose tolerance (IGT) (n = 15)
and type 2 diabetes (n = 18). All subjects
with type 2 diabetes were of South Asian
origin except one subject, who was Afro-
Caribbean. Similarly, all healthy control
subjects were South Asian in origin except
one, who was Afro-Caribbean.
All subjects were nonsmokers. Screen-
ing blood tests were performed for both
baseline measurements to qualify for the
study, as well as to assess glucose control.
Routine blood tests included renal func-
tion, glucose, HbA1c, and full cholesterol
proﬁle. All subjects had their height,
weight, abdominal circumference, and
BMI measurements taken using standard
equipment. Blood samples were taken ei-
ther from the right or left antecubital vein
in a sitting position. Blood pressure was
checked with a blood pressure monitor
on the left arm and rechecked after 2 min.
Finally, a 12-lead electrocardiogram was
performed using the same machine for
the duration of the study. Subjects in-
cluded in the study had a normal resting
electrocardiogram, normal renal function
tests and blood pressure, and no history
of vascular disease. Detailed medical drug
histories were taken on medications, and
those subjects on medication considered
to lead to a change in inﬂammatory status
were excluded, including the thiazolidine-
diones. Ethical approval was obtained from
the local research ethics committee, and all
patients gave written consent.
All research subjects (n = 54) with and
without type 2 diabetes were given a high-
fat meal (standardized meal: 75 g fat, 5 g
carbohydrate, 6 g protein) after an over-
night fast of 12–14 h, as previously de-
scribed (30). The cohort consisted of
nonobese control (NOC) subjects (age
39.9 6 11.8 years [mean 6 SD], BMI
24.9 6 3.2 kg/m2, n = 9) obese subjects
(age 43.8 6 9.5 years, BMI 33.3 6 2.5
kg/m2, n = 15) subjects with IGT (age
41.7 6 11.3 years, BMI 32.0 6 4.5
kg/m2, n = 12), and type 2 diabetic sub-
jects (age 45.4 6 9.6 years, BMI 30.3 6
4.5 kg/m2, n = 18). Blood samples were
drawn at baseline (0 h) and postprandially
(1, 2, 3, and 4 h), and endotoxin and lipid
levels were measured.
In vivo assessment of the
biochemical proﬁle
On the assigned date, fasting blood samples
were collected from participating subjects,
and lipid proﬁles and fasting plasma glucose
were determined using routine laboratory
methods undertaken in the biochemistry
laboratory at University Hospital Coven-
try and Warwickshire. In brief, the routine
blood tests included renal function, glucose,
HbA1c, and a full cholesterol proﬁle (TGs,
HDL, and LDL), as noted in Table 2. Insulin
measurements were performed by a solid-
phase enzyme ampliﬁed sensitivity multi-
plex immunoassay (Millipore, Hertfordshire,
U.K.), and glucose was measured by a glu-
cose oxidase method (YSL 200 STAT plus).
Homeostasis model assessment for insulin
resistance (HOMA-IR) was calculated for
all patients using the HOMA formula:
HOMA-IR = fasting insulin (mU/L) 3
plasma glucose (mmol/L)/22.5.
Analysis of circulating
endotoxin levels
Serum endotoxin was analyzed using a
commercially available QCL-1000 LAL
End Point Assay (Lonza, Allendale, NJ).
The assay, and the values given by the
manufacturer for intra-assay coefﬁcient of
variation (CV) (3.96 0.46) and interassay
CV (9.6 6 0.75), have been validated in
our laboratory, as detailed previously (10).
Statistical analysis
For assessment of the different variables,
statistical analysis was undertaken
using a paired Student t test, for intra-
comparison of hourly time points versus
baseline, and an unpaired Student t test
for inter-comparisons. The threshold for
signiﬁcance was P, 0.05. Data in the text
and ﬁgures are presented as means6 SD
or means 6 SEM. Correlations were de-
termined with a Pearson correlation. Var-
iables with a non-Gaussian distribution
were logarithmically or square root trans-
formed, as deemed appropriate, before
statistical analysis. All statistics were per-
formed on SPSS version 17.0.
RESULTS
Baseline characteristics across
groups
Table 1 shows the anthropometric data.
Table 2 shows the metabolic baseline
and hour time point characteristics of
the four groups analyzed in this study.
Age did not differ signiﬁcantly between
the groups, whereas BMI was altered
across the groups, with the NOC group
possessing the lowest BMI (24.9 6 3.2
kg/m2) (Table 1). The other three groups
(obese: 33.3 6 2.5 kg/m2***↑ Q:3; IGT:
32.06 4.5Kgm2***↑, and type 2 diabetes:
30.3 6 4.5 kg/m2**↑ subjects; P value;
***P, 0.001, **P, 0.01) differed signif-
icantly compared with NOC subjects,
whereas the type 2 diabetic group ex-
hibited a signiﬁcantly lower BMI than
the obese cohort (P, 0.05).Waist circum-
ference followed a similar pattern to the
BMI data. NOC subjects’ waist circumfer-
ence was 86.9 6 8.25 cm versus obese
(108.9 6 17.9 cm***↑), IGT (106.4 6
10.37 cm***↑), and type 2 diabetes
(100.1 6 10.2 cm**↑) subjects (Table 1).
The mean systolic blood pressure (SBP)
levels of the groups were similar across all
groups and did not change signiﬁcantly
over the 4-h duration, which was also
noted for the diastolic blood pressure
(DBP) levels (NOC subjects: SBP 128.2 6
9.7 mmHg, DBP 72.3 6 10.0 mmHg;
obese: SBP 128.2 6 10.7 mmHg, DBP
3.4 6 7.8 mmHg; IGT: SBP 127.3 6
10.1 mmHg, DBP 75.1 6 8.8 mmHg;
and type 2 diabetes: SBP 129.1 6 10.1
mmHg, DBP 74.56 6.9 mmHg).
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Postprandial endotoxin levels
As anticipated, the baseline NOC
group had signiﬁcantly lower fasting
plasma glucose levels than the type 2 di-
abetic group, while showing similar glu-
cose levels to the obese and IGT cohorts
(NOC: 4.7 6 0.69 mmol/L vs. type 2 di-
abetes: 8.16 1.8mmol/L***↑; IGT: 5.66
1.2 mmol/L; obese IGT: 4.9 6 0.93
mmol/L; ***P , 0.001). HbA1c was sim-
ilar in the obese and NOC groups but
was signiﬁcantly higher in the IGT and
type 2 diabetic groups (NOC: 5.9 6
0.31% vs. type 2 diabetes: 7.5 6 1.12%
***↑; IGT: 6.3 6 0.47%*↑; obese IGT:
5.9 6 0.49%; ***P , 0.001, *P ,
0.05). Within each cohort, glucose levels
were not signiﬁcantly altered over the 4-h
postprandial time period.
The baseline lipid proﬁle across the
groups was comparable. Serum endotoxin
levels were signiﬁcantly lower in the base-
line NOC group compared with the IGT
and type 2 diabetic groups (NOC: 3.3 6
0.15EUQ:4 /mL vs. obese: 5.160.94EU/mL↑;
IGT 5.7 6 0.10 EU/mL**↑; type 2 diabe-
tes: 5.3 6 0.54 EU/mL*↑; **P , 0.01,
*P , 0.05; Fig. 1A, Table 2).
Postprandial change in endotoxin
levels over time in individual groups
Postprandial exposure to a high-fat meal
led to a signiﬁcant rise in endotoxin levels
in obese subjects (baseline: 5.1 6 0.94
EU/mL; 1 h: 4.2 6 0.71 EU/mL; 2 h:
6.2 6 0.49* EU/mL: 3 h: 7.8 6 0.76**
EU/mL; 4 h: 7.7 6 0.58** EU/mL; **P
, 0.01, *P, 0.05; Fig. 1A, Table 2); IGT
(IGT: baseline: 5.7 6 0.10 EU/mL; 1 h:
5.86 0.22 EU/mL; 2 h: 5.56 1.0 EU/mL:
3 h: 7.46 0.26* EU/mL; 4 h: 7.56 0.20*
EU/mL; *P, 0.05, Fig. 1A, Table 2), and
type 2 diabetic subjects (baseline: 5.3 6
0.54 EU/mL; 1 h: 5.5 6 0.44 EU/mL;
2 h: 5.8 6 0.34 EU/mL; 3 h: 9.8 6 1.2**
EU/mL; 4 h: 14.26 3.0** EU/mL; **P,
0.01, Fig. 1A, Table 2) over the 4-h time
period. In the NOC group, whereas there
was a rise in circulating endotoxin over
the 4-h period, this trend did not reach
signiﬁcance past 1 h (Fig. 1A, Table 2).
Fasting endotoxin levels showed a posi-
tive correlation with fasting TG levels in
the whole cohort (r = 0.303, P = 0.026).
Further examination of this relationship
postprandially identiﬁed the positive corre-
lation strengthened over time, with the
strongest relationship between endotoxin
and TG noted at 2 and 3 h, respectively
(2-h time point: r = 0.531, P, 0.001; 3-h
time point: r = 0.498, P , 0.001) with a
decline by 4 h after feeding (r = 0.434, P =
0.001). No further correlations with any
other parameters were observed, and those
noted were not inﬂuenced by age or sex.
Postprandial Change in endotoxin
levels between groups
Fasting endotoxin levels were signiﬁcantly
higher in IGT and type 2 diabetic subjects
than inNOCsubjects (72.7%** and60.6%*
increase, respectively; **P , 0.01, *P ,
0.05, Fig. 2B and C). However, during the
postprandial 4-h time period, the circulat-
ing endotoxin levels in both obese and IGT
subjects diminished to ;20% higher than
that of the NOC (4 h, Fig. 2A and B),
whereas circulating endotoxin levels were
sustained at signiﬁcantly higher levels in the
type 2 diabetic subjects than in the NOC
subjects (4 h, Fig. 2C, P, 0.05).
Postprandial changes in lipids over
time in individual groups
Postprandial exposure to a high-fat meal
led to a signiﬁcant rise in TG levels in
NOC, IGT, and type 2 diabetic subjects
after 1 h (P , 0.05). Although the obese
subjects followed the same trend, TGs
levels were only signiﬁcantly altered after
2 h of feeding Q:5(P, 0.05; Fig. 1B, Table 2).
Total cholesterol remained relevantly
unaltered over the 4-h period within all
four groups (Table 2). In addition, no
change was noted in LDL cholesterol and
HDL cholesterol for the NOC subjects over
the 4-h period (Table 2). LDL cholesterol
and HDL cholesterol in the other three
groups did show signiﬁcant individual
group changes over time. For all metabolic
states, LDL and HDL cholesterol signiﬁ-
cantly changed (increased and reduced, re-
spectively; P , 0.05; Table 2), whereas
levels in NOC subjects were not altered.
Postprandial changes in lipid
levels between groups
Fasting total cholesterol, TG, LDL choles-
terol, and HDL cholesterol levels were com-
parable at baseline within the four groups
and did not differ signiﬁcantly through-
out the 4-h duration (Fig. 1B; Table 2).
Table 1dAnthropometric data for the different cohorts
Normal group Obese group IGT group
Type 2 diabetic
group P
n 9 15 12 18
Age (years) 39.9 6 11.8 43.8 6 9.5 41.7 6 11.3 45.4 6 10.1 NS
Sex (M:F) 6:3 10:5 7:5 11:7
Ethnicity Asian, n = 8 Afro-
Caribbean, n = 1
Asian, n = 15 Asian, n = 12 Asian, n = 17
Afro-Caribbean, n = 1
BMI# (kg/m2) 24.9 6 3.2 33.3 6 2.5 32.0 6 4.5 30.3 6 4.5 Normal vs. obese: P , 0.001;
normal vs. IGT: P = 0.001;
normal vs. T2DM: P = 0.003;
IGT vs. obese: NS; IGT vs. T2DM:
NS; obese vs. T2DM: P = 0.019
Waist circumference (cm) 86.9 6 8.25 108.9 6 17.9 106.4 6 10.37 100.1 6 10.2 Normal vs. obese: P = 0.001;
normal vs. IGT: P , 0.001;
normal vs. T2DM: P = 0.002;
IGT vs. obese: NS; IGT vs. T2DM:
NS; obese vs. T2DM: NS
Estimated glomerular
ﬁltration rate# 105.62 6 19.71 91.07 6 17.40 105.92 6 19.77 92.28 6 24.36 NS
Data are means6 SD unless otherwise indicated. T2DM, type 2 diabetes. #Data with a non-Gaussian distribution that were transformed before statistical analysis.
care.diabetesjournals.org DIABETES CARE, VOLUME 35, FEBRUARY 2012 3
Harte and Associates
CONCLUSIONSdThis is the ﬁrst
study to examine the comparative and dif-
ferential changes in circulating endotoxin
after a SFA meal from subjects with and
without type 2 diabetes, obesity, or IGT.
The novel data highlight that a SFA meal
increases circulating endotoxin levels in
all subjects irrespective of their metabolic
status, although circulating endotoxin
shows dramatic postprandial changes in
the high–metabolic risk groups.More spe-
ciﬁc comparative analysis of NOC subjects
versus subjects with type 2 diabetes at 4 h
postprandial identiﬁed that the latter had
a mean endotoxin level 125.4% higher
than that of NOC subjects. Cumulative
data derived from the fasting state and
the SFA postprandial state indicate that
type 2 diabetic subjects are subjected to
336% more circulating endotoxin than
NOC subjects over the 4-h duration. In
comparison to other metabolic states, the
obese and IGT subjects were still subjected
to 167 and 198.5% more circulating en-
dotoxin than NOC subjects. As such, en-
dotoxin, which is considered a potential
mediator of chronic low-grade inﬂamma-
tion, is considerably higher in the state of
type 2 diabetes, with implications for a
continual inﬂammatory state, as other ar-
ticles have observed (15,16,28,29).
While our previous studies have
shown signiﬁcant associations in the fas-
ted state among circulating endotoxin,
lipoprotein patterns, and anthropometric
data (8,10,11,14–17), these current stud-
ies have sought to establish whether en-
dotoxin acutely changes postprandially
and whether this is altered by differing
metabolic states. By undertaking this,
our current studies have highlighted
subtle but signiﬁcant differences in how
endotoxin levels change in the postpran-
dial period. After a SFA meal, the NOC
endotoxin levels rose over the 4-h dura-
tion, but circulating levels did not increase
signiﬁcantly. In contrast, in the obese and
IGT groups, there was a signiﬁcant rise in
endotoxin, which appeared to plateau by
4 h. However, at the 4-h time point, both
the IGT and obese groups’ endotoxin lev-
els were much lower than those of the type
2 diabetic subjects, since the levels of en-
dotoxin in the type 2 diabetic subjects ap-
peared to still be rising 4 h after a SFAmeal Q:6.
Circulating endotoxin in the type 2 diabetic
group, after 4 h, did not appear to normal-
ize, which suggests the cumulative expo-
sure to endotoxin after a high SFA meal is
disproportionately high comparedwith any
other group. Furthermore, in the type 2 di-
abetic subjects, the rising endotoxin levels
may be further compounded by the refeed-
ing stage. These data appear to indicate
that a person eating three high-SFA meals
each day may encounter endotoxin levels
Table 2dVariable data for the different cohorts
Baseline 1 h 2 h 3 h 4 h
Normal group
Triglycerides# (mmol/L) 1.1 6 0.07 1.3 6 0.08* 1.8 6 0.08*** 2.2 6 0.2** 2.4 6 0.27**
Total cholesterol (mmol/L) 4.9 6 0.95 5.1 6 0.85 5.1 6 0.73 5.1 6 0.94 5.2 6 0.81
LDL cholesterol# (mmol/L) 3.2 6 0.04 3.2 6 0.03 3.1 6 0.03 2.82 6 0.04* 2.79 6 0.04
HDL cholesterol# (mmol/L) 1.1 6 0.004 1.1 6 0.004 0.98 6 0.03 1.06 6 0.004 1.03 6 0.008
TNF-a# (pg/mL) 8.0 6 2.3 8.1 6 2.2 7.4 6 2.0 7.4 6 1.8 8.0 6 2.0
Leptin# (ng/mL) 16.8 6 4.8 17.0 6 5.3* 14.6 6 4.0* 13.6 6 3.5* 14.7 6 4.4
Endotoxin# (EU/mL) 3.3 6 0.15 4.0 6 0.17* 4.32 6 0.19 5.5 6 0.64 6.3 6 1.4
Obese group
Triglycerides# (mmol/L) 1.6 6 0.08 1.7 6 0.08 2.3 6 0.10*** 2.7 6 0.12*** 3.0 6 0.14***
Total cholesterol (mmol/L) 5.3 6 0.80 5.1 6 0.67 5.1 6 0.99 5.3 6 1.0 5.2 6 0.76
LDL cholesterol# (mmol/L) 3.56 6 0.04 3.34 6 0.02 3.0 6 0.05*** 3.0 6 0.06*** 2.9 6 0.04***
HDL cholesterol# (mmol/L) 0.92 6 0.01 0.90 6 0.01 0.84 6 0.01* 0.85 6 0.008** 0.81 6 0.01***
TNF-a# (pg/mL) 8.4 6 1.3 8.4 6 1.4 7.8 6 1.6 7.5 6 1.4* 7.5 6 1.4*
Leptin# (ng/mL) 25.6 6 3.1 23.3 6 2.7*** 20.7 6 2.3 21.7 6 2.6 21.4 6 2.9***
Endotoxin# (EU/mL) 5.1 6 0.94 4.2 6 0.71 6.2 6 0.49 7.8 6 0.76** 7.7 6 0.58**
IGT group
Triglycerides# (mmol/L) 1.3 6 0.03 1.5 6 0.04*** 1.9 6 0.07*** 2.5 6 0.15*** 2.5 6 0.15***
Total cholesterol (mmol/L) 4.9 6 0.80 4.7 6 0.74 4.8 6 0.74 4.8 6 0.77 4.8 6 0.77
LDL cholesterol# (mmol/L) 3.24 6 0.04 3.08 6 0.03 2.9 6 0.03** 2.6 6 0.04** 2.66 6 0.05**
HDL cholesterol# (mmol/L) 0.88 6 0.008 0.86 6 0.008 0.82 6 0.006*** 0.81 6 0.008*** 0.77 6 0.01***
TNF-a# (pg/mL) 4.4 6 2.1 4.3 6 2.0 4.3 6 2.0 4.1 6 2.0 4.3 6 2.1
Leptin# (ng/mL) 37.0 6 2.7 32.6 6 2.7*** 32.0 6 2.7* 31.1 6 3.0** 33.0 6 3.3**
Endotoxin# (EU/mL) 5.7 6 0.10 5.8 6 0.22 5.5 6 1.0 7.4 6 0.26* 7.5 6 0.20*
Type 2 diabetic group
Triglycerides# (mmol/L) 1.4 6 0.03 1.6 6 0.05*** 2.2 6 0.08*** 2.8 6 0.12*** 3.1 6 0.13***
Total cholesterol (mmol/L) 5.0 6 1.0 4.8 6 0.95* 4.8 6 0.91 5.0 6 1.0 4.9 6 0.93
LDL cholesterol# (mmol/L) 3.17 6 0.11 2.9 6 0.07*** 2.6 6 0.10*** 2.4 6 0.16** 2.4 6 0.14***
HDL cholesterol# (mmol/L) 1.0 6 0.02 1.0 6 0.02 0.94 6 0.02*** 0.92 6 0.02*** 0.86 6 0.02***
TNF-a# (pg/mL) 8.6 6 2.0 8.4 6 2.0 8.4 6 2.0 8.3 6 1.8 8.1 6 2.3
Leptin# (ng/mL) 18.1 6 3.5 20.0 6 5.0*** 18.7 6 3.7 18.2 6 3.4 15.2 6 3.3
Endotoxin# (EU/mL) 5.3 6 0.54 5.5 6 0.44 5.8 6 0.34 9.8 6 1.2** 14.2 6 3.0**
Data are means 6 SD. TNF, tumor necrosis factor. *Signiﬁcant difference compared with baselineQ:12 . #Data with a non-Gaussian distribution that were transformed
before statistical analysis. *P , 0.05. **P , 0.01. ***P , 0.001.
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that remain perpetually high, since refeed-
ing may increase the levels. As such, fasted
endotoxin data, while important, may ap-
pear to miss the daily variation, as feeding
data appear to show. The type of meal is
clearly important, since previous studies
highlight that dietary changes alter circulat-
ing endotoxin and inﬂuence inﬂammation,
even in healthy subjects (13,28). In addi-
tion, recent studies have reported that the
simultaneous ingestion of certain “healthy”
food groupswith saturated fat can negate an
increase in circulating endotoxin and the
customary inﬂammatory response (29). Be-
cause it is acknowledged that obese and
type 2 diabetic subjects tend to eat high
SFA without correspondingly high levels
of fruit or healthy foods, this diet would
clearly affect their endotoxin and inﬂamma-
tory status (28,31,32). Therefore, a high
SFA intake could represent a continual in-
ﬂammatory insult for type 2 diabetic sub-
jects daily.
In the obese and IGT groups, the
postprandial 4-h endotoxin levels appear
to plateau, while still remaining high com-
pared with NOC subjects. Subsequently,
another SFA meal may compound the
circulating endotoxin levels further within
the obese and IGT groups; therefore, the
type and frequency of meals may signiﬁ-
cantly affect the metabolic risk. In addition
to the type of meal, the food intake fre-
quency is also relevant, although cur-
rently, there are few studies examining the
importance of this. Previous studies in-
dicate no difference between a diet based
on three meals a day or a diet comprising
smaller meals and snacks, with regard to
the long-term effects on glucose, lipid, or
insulin responses; although, the unknown
acute postprandial effects on the inﬂam-
matory status may have a more profound
long-term impact (32,33). In addition,
previous studies have often stressed the
division of food intake should be based
on individual preference, with no clear
recommendations on pattern of food in-
take.Within type 2 diabetes clinics, the rec-
ommendation for patients is to consume
ﬁve smaller meals per day. This step may
reduce the potentially overwhelming orexi-
genic effects patients might experience
with only three meals a day, as well as the
potential spikes in insulin, although the
data do not necessarily give clear insight
into these beneﬁts (32,33). Based on these
current studies, more frequent saturated fat
exposure may exacerbate both endotoxin
and inﬂammation further. Furthermore,
smaller more frequent meals have the po-
tential to allow endotoxin to spike several
times a day, thus activating the innate im-
mune system within adipose tissue with-
out desensitization (9,10,28,29). As such,
the resulting downstream production of
diabetogenic cytokines would be in con-
tinuous production, as previous in vivo
and in vitro studies have demonstrated
(9,10,17,28,29). The TG levels did not
differ signiﬁcantly across the four groups
of subjects at any of the time points; how-
ever, the TG levels did increase from base-
line to 4 h within each group, in a similar
pattern to circulating endotoxin, but most
signiﬁcantly in the metabolic risk subjects
(obese, IGT, and type 2 diabetes), while
also demonstrating an associationwith en-
dotoxin, over the 4-h period (10,16,17).
The three differentmetabolic states showed
signiﬁcantly higher fasting TG levels than
NOC subjects, which postprandially be-
came further exacerbated in the obese and
type 2 diabetic subjects.
Unsurprisingly, postprandial TG levels
increased in a similar pattern to circulating
endotoxin, while also demonstrating an as-
sociation, over the 4-h period (10,16,17).
The three differentmetabolic states showed
no signiﬁcant differences in TG levels com-
pared with levels in NOC subjects. How-
ever, the signiﬁcant correlation between
fasting TG and endotoxin levels conﬁrms
previous studies in which an association
between these two metabolic parameters
had been observed (10,16,17). Our data
indicated that the association between
TGs and circulating endotoxin became
stronger in the postprandial state each
hour over the 4-h duration, substantiating
previous evidence that lipids mediate the
transfer of endotoxin from the gastrointes-
tinal tract into the circulation (9,11).
Concurrent Q:7; 8with postprandial changes
in TGs the LDL/HDL ratio reduced com-
pared with baseline measurements, specif-
ically HDL was signiﬁcantly reduced at
time points postprandially within all except
the NOC group, potentially due to parallel
elevations in chylomicrons and VLDL, as
noted in other studies (34–36). Whereas
its established that obese type 2 diabetic
patients suffer from a syndrome of high se-
rum TG and low HDL (37), low levels of
Figure 1dChanges in circulating endotoxin levels (A) and triglyceride levels (B) in NOC, IGT, obese, and type 2 diabetic (T2DM) subjects.
Endotoxin and triglyceride levels were measured at baseline and then, after a high SFA meal, at each hour postprandially over a 4-h duration. Each
point on the graph represents the mean value for each cohort (6 SEM).
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HDL are also associated with low levels of
sCD14Q:9 (Fig. 3) (38; 10 ). This result corre-
sponds with the data that endotoxin has
been demonstrated to bind to HDL in the
presence of sCD14 and lipopolysaccharide
binding protein (39,40), an enzyme in-
volved in presentation of endotoxin to
sCD14. This outcome supports a role for
HDL in the immunological response to en-
dotoxin. Therefore, a reduction in HDL
would reduce the removal of endotoxin
further and exacerbate the inﬂammatory
status, further compounded by higher cir-
culating levels of endotoxin in the obese,
IGT, and type 2 diabetic subject groups.
Whereas our studies have highlighted
the impact of metabolic disease status on
circulating endotoxin, it is important to
recognize the limitations of the study.
In all research, it is always preferable to
increase the subject numbers that com-
prise each cohort. In the present studies, in-
creased numbers might have noted different
postprandial responses to the high-fat
meal within each cohort, if the groups
were further subdivided. However, in light
of this being a cross-sectional study, in
which intra- and inter-comparisons can be
made, the numbers do not detract from the
ﬁndings. Consistent and signiﬁcant trends
were observed within the subjects over
the 4-h postprandial duration, and differ-
ences between the cohortswere duly noted.
We also recognize that the research sub-
jects were given a very high-fat meal (75 g),
roughly equivalent to their total daily intake
of fat, which some observers might argue is
an excessive (nonphysiological) amount of
fat. However, despite the fat load, there
was no signiﬁcant change in endotoxin,
cholesterol, LDL, or HDL levels postpran-
dially in the NOC subjects in contrast to
the other groups examined; the fat load
administered was based on previous stud-
ies (30). Furthermore, administration of
75 g glucose could also be considered
high and would far exceed normal intake
of glucose in one sitting, yet this is standard
clinical practice for assessment of insulin
sensitivity, whereas the fat load is only cur-
rently used as a research tool. No ill effects
were noted in any of the patients during or
after the study.
In summary, our current data shed
new light on our understanding of met-
abolic endotoxinemia in the postprandial
state in metabolic disease. Our ﬁndings
suggest that circulating endotoxin levels
change depending on whether you are
prediabetic, are nonobese, are obese, have
IGT, or have type 2 diabetes. Further,
circulating endotoxin levels noted in sub-
jects with type 2 diabetes, at 4 h post-
prandial high-fat meal, far exceed our
previous understanding based on other
feeding studies in healthy subjects or
the fasted state in type 2 diabetic subjects.
Therefore, our 4-h data suggest a much
higher inﬂammatory risk than previous
Figure 2dIncrease in endotoxin levels between the NOC subjects and the obese (A), IGT (B), and type 2 diabetic (T2DM) (C) subjects from baseline
to 4 h after a high-fat meal. Endotoxin is measured in EU/mL, and the percentage increase compared with NOC is also shown.
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studies have indicated. These ﬁndings
highlight the point that requesting pa-
tients to eat smaller, more frequent meals
may actually increase their inﬂammatory
risk further, especially in subjects with
type 2 diabetes (who tend to favor high-fat
foods) (32). Finally, while the most obvi-
ous solution to metabolic endotoxinemia
appears to be to reduce saturated fat in-
take, the Western diet is not conducive
to this mode of action, and it is difﬁcult
for patients to comply with this request.
Therefore, we need to understand the
complexity of diet, meal frequency, and
its acute effects on inﬂammatory risk and
give more guidelines to particular subject
groups, since leaving food intake to “individ-
ual preferences” appears not to represent a
beneﬁcial solution to reduce the inﬂamma-
tory state in metabolic at-risk subjects.
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